drugset / Trial / NCT03086044

Transplanting Hepatitis C Positive Organs

NCT03086044

Phase 4 Unknown 148 enrolled Brigham and Women's Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, pilot safety and efficacy trial for adults who are active on the heart, lung, or kidney transplantation lists and are eligible to receive an organ from an increased risk donor who has evidence of active or prior hepatitis C infection (HCV).

Timeline

Start
2017-03-01
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Sofosbuvir Small molecule 400 mg
Subject velpatasvir Other / unclassified 100 mg